Prenatal Dexamethasone Treatment of Congenital Adrenal Hyperplasia: Are We Any Closer to Considering It Safe?

First trimester dexamethasone treatment is not associated with alteration in resting-state connectivity at adolescent or adult age

(2022) Valeria Messina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Early adversity and insulin: neuroendocrine programming beyond glucocorticoids

(2021) Aashita Batra et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age

(2020) Annelies van’t Westeinde et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

First Trimester DEX Treatment Is Not Associated with Altered Brain Activity During Working Memory Performance in Adults

(2020) Annelies van’t Westeinde et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of prenatal dexamethasone treatment in offspring at risk for congenital adrenal hyperplasia due to 21‐hydroxylase deficiency: A systematic review and meta‐analysis

(2019) Lizhen Xu et al.   CLINICAL ENDOCRINOLOGY

Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline

(2018) Phyllis W Speiser et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM